Credit Suisse Reiterates Outperform on Hims & Hers Health, Maintains $14 Price Target
Portfolio Pulse from richadhand@benzinga.com
Credit Suisse analyst Jonathan Yong has reiterated an Outperform rating on Hims & Hers Health (NYSE:HIMS) and maintained a $14 price target.
August 08, 2023 | 12:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Credit Suisse has reiterated an Outperform rating on Hims & Hers Health and maintained a $14 price target.
The reiteration of an Outperform rating by Credit Suisse indicates a positive outlook for Hims & Hers Health. The maintained price target of $14 suggests that the analyst believes the stock is still undervalued, which could lead to upward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100